As the UK moves towards the end of the transition period for leaving the EU, the application of the EU-wide regime for medicines and medical devices to the UK market is coming to an end. This potentially leaves a gap for maintaining and updating existing rules. It also presents an opportunity for a change of direction for the UK in line with current concerns over regulatory transparency and patient involvement, as we have seen in the recent report of the Independent Medicines and Medical Devices Safety Review, chaired by Baroness Julia Cumberlege, First Do No Harm.
You can read more on the Cumberlege report and the patient safety recommendations in Jill Mason's blog here. And to find out more on the likely impact of the Medicines and Medical Devices Bill on life science regulation read James Fry's article, Life sciences regulation after Brexit - a new direction here.